Last reviewed · How we verify
NCT04135664
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Phase 3 trial testing esophagectomy in Esophageal Cancer in 176 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Shanghai Chest Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 176 |
| Start date | 1 September 2019 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 6 locations across China |
Drugs / interventions tested
- esophagectomy
- chemoradiation — full drug profile →
- active surveillance
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
Sponsor
Shanghai Chest Hospital
Who can join
Adults 18 to 75, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ad-ESD trial is phase III randomized trial to compare adjuvant esophagectomy and chemoradiation for patients with clinical stage N0 and pathological stage T1b squamous cell carcinoma (after endoscopic submucosal dissection).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current status and perspectives of esophageal cancer: a comprehensive review.
Jiang W, Zhang B, Xu J, Xue L, et al · · 2025 · cited 28× · PMID 39723635 · DOI 10.1002/cac2.12645 -
Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial).
Yang Y, Su Y, Zhang X, Liu J, et al · · 2020 · cited 11× · PMID 32611448 · DOI 10.1186/s13063-020-04461-5 -
Long-term survival in esophagectomy for early-stage esophageal cancer versus endoscopic resection plus additional chemoradiotherapy: a systematic review and meta-analysis.
Chen Y, Wang YY, Dai L, Chen MW. · · 2023 · cited 5× · PMID 37691683 · DOI 10.21037/jtd-23-376 -
Adjuvant Esophagectomy versus Definitive Chemoradiotherapy for Patients with Clinical Stage N0 and Pathological Stage T1b Esophageal Squamous Cell Carcinoma After Endoscopic Submucosal Dissection: Study Protocol for A Multicenter Randomized Controlled Trial (Ad-ESD Trial)
Yang Y, Su Y, Zhang X, Liu J, et al · · 2020 · DOI 10.21203/rs.2.24793/v1
Verify or expand the search:
- PubMed search for NCT04135664
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of esophagectomy
Trials testing the same drug.
- NCT07312526 — Shanghai Clinical Cohort - Esophageal Cancer · completed
- NCT05812235 — Bone Microstructure by Using HR-pQCT After Esophagectomy · not yet recruiting
- NCT05357846 — PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) · Phase 3 · recruiting
- NCT03094351 — Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy · Phase 3 · unknown
- NCT03378869 — Perioperative Management and Outcomes of Minimally Invasive Esophagectomy · completed
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other Shanghai Chest Hospital trials
Trials by the same sponsor.
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
- NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
- NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
- NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04135664 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
- Last refreshed: 22 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04135664.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing